Summary
Purpose: Phase II multicenter cooperative group study investigated the efficacy and toxicity of the novel anti-microtubule agent dolastatin-10 in patients with advanced breast cancer.
Patient and methods: Twenty-one patients with measurable metastatic breast cancer were treated with dolastatin-10 at a dose of 400 mcg/m2 by intravenous bolus once every 3 weeks. Patients must have received a total of 1 or 2 prior chemotherapy regimens and have an Eastern Cooperative Oncology Group performance status of 0–2. Patients received this treatment as either a first (n = 11) or second-line (n = 10) chemotherapy for metastatic disease. Eighteen patients (86%) had received a prior anthracycline. The National Cancer Institute provided the dolastatin-10.
Results: One out of 21 patients (5%; 95% CI: 0–24%) achieved a partial remission for a duration of 113 days. Four patients maintained stable disease for a median of 87 days. A total of 58 courses of dolastatin-10 were administered. Patients received a median of two cycles of dolastatin-10. Hematologic toxicity was moderate, with 8 patients developing grade 4 neutropenia, and 5 with grade 3 neutropenia; one grade 3 febrile neutropenia was observed. These episodes of grade 3 and 4 neutropenia were experienced on 36% of the treatment cycles. Non-hematologic toxicity was uncommon.
Conclusion: While the toxicity profile of dolastatin-10 was acceptable, it had minimal activity in this advanced breast cancer study. We are not pursuing further clinical trials of this agent in the setting of advanced breast cancer.
Similar content being viewed by others
References
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer Statistics, 2005. CA Cancer J Clin 55: 10–30, 2003
Perez EA: State of the Art Therapy for Metastatic Breast Cancer. Cancer Res Ther Control 9: 261–266, 1999
Pettit GR, Kamano Y, Herald CL, Tuinmann AA, Boettner FE, Kizu H, Schmidt JM, Baczynskyj L, Tomer KB, Bontems RJ: The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin-10. J Am Chem Soc 109: 6883–6885, 1997
Kalemkerian GP, Ou X, Adil MR, et al. Activity of dolastatin-10 against small-cell cancer in vitro and in vivo: Induction of apoptosis and bcl-2 modification. Cancer Chemother Pharmacol 43: 507–515, 1999
Bai R, Pettit GR, Hamel E: Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid-binding domain. Biochem Pharmacol 39: 1941–1949, 1990
Bai RL, Pettit GR, Hamel E: Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 265: 17141–17149, 1990
Bai R, Roach MC, Jayaram SK, Barkoczy J, Pettit GR, Luduena RF, Hamel E: Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity. Biochem Pharmacol 45: 1503–1515, 1993
Hamel E: Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther 55: 31–51, 1992
Pettit GR, Singh SB, Hogan F: The absolute configuration and synthesis of natural dolastatin-10. J Am Chem Soc 111: 5463–5465, 1989
Hu ZB, Gignac SM, Quentmeier H, Pettit GR, Drexler HG: Effects of dolastatins on human B-lymphocytic leukemia cell lines. Leuk Res 17: 333–339, 1993
Beckwith M, Urba WJ, Longo DL: Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15. J Natl Cancer Inst 85: 483–488, 1993
Kingston RD, Fielding JW, Palmer MK: Peri-operative heparin: A possible adjuvant to surgery in colo-rectal cancer? Int J Colorectal Dis 8: 111–115, 1993
Pitot HC, McElroy EA Jr., Reid JM, Windebank AJ, Sloan JA, Erlichman C, Bagniewski PG, Walker DL, Rubin J, Goldberg RM, Adjei AA, Ames MM: Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 5: 525–531, 1999
Alroy I, Yarden Y: The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions. FEBS Letters 410(1): 83–86, 1997
Maki A, Mohammad R, Raza S, Saleh M, Govindaraju KD, Pettit GR, al-Katib A: Effect of dolastatin 10 on human non-Hodgkin’s lymphoma cell lines. Anticancer Drugs 7: 344–350, 1996
Kalemkerian GP, Ou X, Adil M, Rosati R, Khoulani M, Madan S, Pettit G: Activity of dolastatin-10 against small-cell lung cancer in vitro and in vivo: Induction of apoptosis and bcl-2 modification. Cancer Chemother Pharmacol 43: 507–515, 1999
Bai R, Friedman SJ, Pettit GR, Hamel E: Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules. Biochem Pharmacol 43: 2637–2645, 1992
Quentmeier H, Brauer S, Pettit GR: Cytotoxic effects of dolastatin-10 and dolastatin-15 on human leukemia cell lines. Leuk Lymphoma 6: 245–250, 1992
May RD, Murphy MJ Jr., Erickson-Miller CL, Tomaszewski JE, Osborn BL, Page JG: Myelotoxicity evaluation of dolastatin-10 (NSC-376128) and swainsonine (NSC-614553) Using murine, canine and human in vitro CFU-GM assays (abstract #2398). Proc Am Assoc Cancer Res 35: 402, 1994
Krug LM, Miller VA, Kalemkerian GP, Kraut MJ, Ng KK, Heelan RT, Pizzo BA, Perez W, McClean N, Kris MG: Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer. Ann Oncol 11: 227–228, 2000
Vaishampayan U, Glode M, Du W, Kraft A, Hudes G, Wright J, Hussain M: Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res 6: 4205–4208, 2000
Margolin K, Longmate J, Synold TW, Gandara DR, Weber J, Gonzalez R, Johansen MJ, Newman R, Baratta T, Doroshow JH: Dolastatin-10 in metastatic melanoma: A phase II and pharmokinetic trial of the California Cancer Consortium. Invest New Drugs 19: 335–340, 2001
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Perez, E.A., Hillman, D.W., Fishkin, P.A. et al. Phase II trial of dolastatin-10 in patients with advanced breast cancer. Invest New Drugs 23, 257–261 (2005). https://doi.org/10.1007/s10637-005-6735-y
Issue Date:
DOI: https://doi.org/10.1007/s10637-005-6735-y